OnZurf probe allows detection of metabolic changes in the small bowel wall
Uppsala, 30 August 2016. A preclinical collaborative study between Umeå University and Skåne University Hospital, Lund showed that placement of the OnZurf probes on small bowel wall allowed detection of anaerobic metabolic changes very early after onset of ischemia.
The results indicate that the extent of metabolic changes, as estimated by lactate levels in retrieved dialysate, was in agreement with ischemia as scored histopathologically. Placement of the OnZurf probes onto the small bowel wall may be a useful, non-invasive tool for early detection of ischemic changes and monitoring of bowel perfusion status following surgery. Read more about the study online at this link.
Continuous monitoring of lactate in patients undergoing surgery may provide an opportunity to detect early signs of ischemia (lack of oxygen). The clinical market seeks systems that allow continuous monitoring of biomarkers in blood and tissue for rapid detection and monitoring of post-operative complications. In Sweden, for instance, many cancer surgeries are conducted annually, in which effective monitoring systems are necessary. The ability to noninvasively monitor for metabolic indicators of ischemia may reduce postoperative complications and the cost of treatment.
Senzime has developed user-friendly products for continuous monitoring of glucose and lactate in fluids such as blood and cell cultures. These monitoring techniques are important — often critical—for patients who have undergone surgery and who are at risk for postoperative complications such as organ ischemia. Senzime’s product OnZurf probe allows continuous biochemical test sampling from target organs.
For further information, please contact: Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com
TO THE EDITORS
About Senzime
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com